Stillbirth Less Likely for Women Receiving Trivalent Flu Vaccine

This article originally appeared here.
Share this content:
Stillbirth Less Likely for Women Receiving Trivalent Flu Vaccine
Stillbirth Less Likely for Women Receiving Trivalent Flu Vaccine

THURSDAY, March 31, 2016 (HealthDay News) -- Women receiving trivalent influenza vaccination are less likely to experience a stillbirth, especially for births occurring just after influenza season, according to a study published online March 30 in Clinical Infectious Diseases.

Annette K. Regan, M.P.H., from the University of Western Australia in Crawley, and colleagues examined the incidence of stillbirth following seasonal trivalent influenza vaccination in a cohort of 58,008 births occurring between April 2012 and December 2013.

The researchers found that 8.8 percent of pregnant women received trivalent influenza vaccination and there were 377 stillbirths. Among unvaccinated and vaccinated women, there were 5.0 and 3.0 stillbirths per 100,000 pregnancy-days, respectively. Stillbirth was 51 percent less likely among vaccinated mothers compared with unvaccinated mothers after adjustment for confounders (adjusted hazard ratio, 0.49). Births occurring just after influenza season had the largest relative reduction in stillbirths (adjusted hazard ratio, 0.33).

"Mothers who received seasonal trivalent influenza vaccination during pregnancy were significantly less likely to experience stillbirth compared with unvaccinated mothers," the authors write. "These results support the safety of seasonal influenza immunization during pregnancy and suggest a protective effect."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »